ATXN3 and prostate carcinoma: Briefly, we transfected four nonoverlapping siRNA mixtures specific for each of the DUBs into prostate cancer cells and found that silencing ATXN3 significantly decreased YAP protein level in LnCap cells (Fig. 1A).